ADCT-502 / ADC Therapeutics  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ADCT-502 / ADC Therapeutics
NCT03125200: Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Terminated
1
21
Europe, US
ADCT-502
ADC Therapeutics S.A.
Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
04/18
04/18

Download Options